Literature DB >> 12742558

Effect of four oral contraceptives on thyroid hormones, adrenal and blood pressure parameters.

I Wiegratz1, E Kutschera, J H Lee, C Moore, U Mellinger, U H Winkler, H Kuhl.   

Abstract

In a double-blind, controlled, randomized, four-arm, bicentric clinical study, the effect of four oral contraceptives (OCs) on thyroid hormone parameters, cortisol, aldosterone, endothelin-1 and angiotensin II was investigated. Four groups composed of 25 volunteers each (ages between 18 and 35 years) were treated for six cycles with monophasic combinations containing 21 tablets with either 30 microg ethinylestradiol (EE) + 2 mg dienogest (DNG) (30EE/DNG), 20 microg EE + 2 mg DNG (20EE/DNG), 10 microg EE + 2 mg estradiol valerate (EV) + 2 mg DNG (EE/EV/DNG) or 20 microg EE + 100 microg levonorgestrel (LNG) (EE/LNG). The study was completed by 91 subjects. Blood samples were taken by venipuncture after at least 12 h fasting on Day 21-26 of the control cycle and on Day 18-21 of the first, third and sixth treatment cycle. There was a significant increase in triiodothyronine (T3) and thyroxine (T4) by 20-40% in all treatment cycles, while thyroid-stimulating hormone was significantly increased only with EE/EV/DNG. Treatment with the DNG-containing OCs caused no change in free T4 (FT4) and a transitory reduction in free T3 (FT3) levels during the first cycle. During intake of EE/LNG, FT4 rose slightly, while FT3 was not altered. The pronounced rise in the serum concentrations of cortisol appeared to be related to the EE dose. During the first three cycles of treatment, no effect on angiotensin II levels was observed, while in the sixth cycle a significant decrease was measured in all treatment groups. The four OCs did not influence the serum concentrations of endothelin-1 and no consistent effects were found concerning those of aldosterone. The results suggest that the three DNG-containing and the LNG-containing low-dose OCs may increase T3, T4 and cortisol due to an elevated binding to serum globulins, while the free proportion of the hormones is not or only slightly changed. Therefore, these OCs have only minor effects on thyroid function, adrenal and blood pressure serum parameters.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12742558     DOI: 10.1016/s0010-7824(03)00006-4

Source DB:  PubMed          Journal:  Contraception        ISSN: 0010-7824            Impact factor:   3.375


  13 in total

Review 1.  Effects of sex and gender on adaptations to space: reproductive health.

Authors:  April E Ronca; Ellen S Baker; Tamara G Bavendam; Kevin D Beck; Virginia M Miller; Joseph S Tash; Marjorie Jenkins
Journal:  J Womens Health (Larchmt)       Date:  2014-11       Impact factor: 2.681

2.  Investigation of the Relationship between MR-Based Supraclavicular Fat Fraction and Thyroid Hormones.

Authors:  Daniela Junker; Jan Syväri; Dominik Weidlich; Christina Holzapfel; Theresa Drabsch; Birgit Waschulzik; Ernst J Rummeny; Hans Hauner; Dimitrios C Karampinos
Journal:  Obes Facts       Date:  2020-06-19       Impact factor: 3.942

Review 3.  Ethinylestradiol/dienogest in oral contraception.

Authors:  Ezequiel F Pérez-Campos
Journal:  Drugs       Date:  2010-04-16       Impact factor: 9.546

4.  Biomarkers of PAH exposure and hematologic effects in subjects exposed to combustion emission during residential (and professional) cooking practices in Pakistan.

Authors:  Atif Kamal; Alessandra Cincinelli; Tania Martellini; Riffat Naseem Malik
Journal:  Environ Sci Pollut Res Int       Date:  2015-09-11       Impact factor: 4.223

5.  Acute HPA axis response to naltrexone differs in female vs. male smokers.

Authors:  Daniel J O Roche; Emma Childs; Alyssa M Epstein; Andrea C King
Journal:  Psychoneuroendocrinology       Date:  2009-10-17       Impact factor: 4.905

Review 6.  Evidence for a Non-Genomic Action of Testosterone in Skeletal Muscle Which may Improve Athletic Performance: Implications for the Female Athlete.

Authors:  Jessica R Dent; Deborah K Fletcher; Michael R McGuigan
Journal:  J Sports Sci Med       Date:  2012-09-01       Impact factor: 2.988

Review 7.  Combined Oral Contraceptive Pill-Induced Hypertension and Hypertensive Disorders of Pregnancy: Shared Mechanisms and Clinical Similarities.

Authors:  Madugodaralalage D S K Gunaratne; Bjorg Thorsteinsdottir; Vesna D Garovic
Journal:  Curr Hypertens Rep       Date:  2021-05-13       Impact factor: 5.369

8.  Effects of a monophasic combined oral contraceptive containing nomegestrol acetate and 17β-oestradiol in comparison to one containing levonorgestrel and ethinylestradiol on markers of endocrine function.

Authors:  Ulla M Ågren; Marjatta Anttila; Kristiina Mäenpää-Liukko; Maija-Liisa Rantala; Hilkka Rautiainen; Werner F Sommer; Ellen Mommers
Journal:  Eur J Contracept Reprod Health Care       Date:  2011-09-26       Impact factor: 1.848

9.  Multinational, multicentre, randomised, open-label study evaluating the impact of a 91-day extended regimen combined oral contraceptive, compared with two 28-day traditional combined oral contraceptives, on haemostatic parameters in healthy women.

Authors:  Rossella E Nappi; Anna Maria Paoletti; Annibale Volpe; Luca Chiovato; Brandon Howard; Herman Weiss; Nancy Ricciotti
Journal:  Eur J Contracept Reprod Health Care       Date:  2014-06-13       Impact factor: 1.848

10.  Effects of oral contraceptives on diurnal profiles of insulin, insulin-like growth factor binding protein-1, growth hormone and cortisol in endurance athletes with menstrual disturbance.

Authors:  A Rickenlund; M Thorén; A Nybacka; J Frystyk; A Lindén Hirschberg
Journal:  Hum Reprod       Date:  2009-10-19       Impact factor: 6.918

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.